1. Home
  2. ANAB vs BLMN Comparison

ANAB vs BLMN Comparison

Compare ANAB & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • BLMN
  • Stock Information
  • Founded
  • ANAB 2005
  • BLMN 1988
  • Country
  • ANAB United States
  • BLMN United States
  • Employees
  • ANAB N/A
  • BLMN N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • BLMN Restaurants
  • Sector
  • ANAB Health Care
  • BLMN Consumer Discretionary
  • Exchange
  • ANAB Nasdaq
  • BLMN Nasdaq
  • Market Cap
  • ANAB 759.5M
  • BLMN 714.5M
  • IPO Year
  • ANAB 2017
  • BLMN 2012
  • Fundamental
  • Price
  • ANAB $22.23
  • BLMN $7.63
  • Analyst Decision
  • ANAB Buy
  • BLMN Hold
  • Analyst Count
  • ANAB 10
  • BLMN 11
  • Target Price
  • ANAB $42.25
  • BLMN $13.75
  • AVG Volume (30 Days)
  • ANAB 559.5K
  • BLMN 2.9M
  • Earning Date
  • ANAB 05-05-2025
  • BLMN 05-07-2025
  • Dividend Yield
  • ANAB N/A
  • BLMN 7.86%
  • EPS Growth
  • ANAB N/A
  • BLMN N/A
  • EPS
  • ANAB N/A
  • BLMN N/A
  • Revenue
  • ANAB $111,872,000.00
  • BLMN $3,930,996,000.00
  • Revenue This Year
  • ANAB N/A
  • BLMN $1.28
  • Revenue Next Year
  • ANAB $9.72
  • BLMN $1.67
  • P/E Ratio
  • ANAB N/A
  • BLMN $8.44
  • Revenue Growth
  • ANAB 387.20
  • BLMN N/A
  • 52 Week Low
  • ANAB $12.21
  • BLMN $6.09
  • 52 Week High
  • ANAB $41.31
  • BLMN $22.34
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 62.32
  • BLMN 45.27
  • Support Level
  • ANAB $20.50
  • BLMN $7.62
  • Resistance Level
  • ANAB $22.84
  • BLMN $8.03
  • Average True Range (ATR)
  • ANAB 1.28
  • BLMN 0.43
  • MACD
  • ANAB 0.12
  • BLMN -0.07
  • Stochastic Oscillator
  • ANAB 83.24
  • BLMN 14.37

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.

Share on Social Networks: